موقع شبرون للتقنية والأخبار- متابعات تقنية:
AstraZeneca submitted a request for the FDA on Wednesday to approve a self-administered nasal flu vaccine for people ages two to 49 years old. The vaccine, FluMist, would be the first at-home vaccine that would allow anyone 18 years of age and older to administer it to themselves and those underage.
If approved, FluMist would be used similarly to other nose sprays by injecting it into the nasal cavity, “providing a convenient new choice for individuals and families who want to protect their loved ones against the flu,” AstraZeneca said in a press release. FluMist is already approved as a flu vaccine, but it currently can only be administered by a health care professional.
AstraZeneca says it hopes FluMist could increase the number of people who get vaccinated against the illness. For the 2021-2022 flu season, 9 million people were sick with the flu according to the Centers for Disease Control and Prevention website. Of those 9 million, approximately 100,000 went to the hospital and 5,000 died from the flu.
Lisa Glasser, head of U.S. medical affairs, vaccines, and immune therapies at AstraZeneca, told Yahoo Finance Tuesday that the push for FDA approval stems from lessons learned during the Covid-19 pandemic.
“We put in people’s hands nasal swabs to test for COVID, which people were very easily able to handle and continue to use,” Glasser said.
She says that the company is confident that the FluMist vaccine will be easy to use and will be shipped with specific directions to inject the nasal syringe. The official date for the vaccine’s release or details surrounding the packaging and shipment process are not yet available.
AstraZeneca says it expects it to be available in the U.S. for the 2024-2025 flu season.
The company did not immediately respond to Gizmodo’s request for more information about the cost of the FluMist vaccine or if it will be covered by insurance.
اكتشاف المزيد من موقع شبرون
اشترك للحصول على أحدث التدوينات المرسلة إلى بريدك الإلكتروني.
